Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhBNP for acute heart failure with chronic renal insufficiency
ChiCTR2500107963Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nesiritide in Acute Heart Failure (AHF) and chronic kidney disease (CKD), sponsored by Tongji Hospital. Primary endpoint: Rate of readmission due to cardiogenic factors or heart failure within 1 month of discharge. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
nesiritide
03
Conditions
Acute Heart Failure (AHF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2500107963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107963.